Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9

1.

Tildrakizumab Efficacy and Safety Are Not Altered by Metabolic Syndrome Status in Patients With Psoriasis: Post Hoc Analysis of 2 Phase 3 Randomized Controlled Studies (reSURFACE 1 and reSURFACE 2).

Lebwohl MG, Leonardi CL, Mehta NN, Gottlieb AB, Mendelsohn AM, Parno J, Rozzo SJ, Menter A.

J Am Acad Dermatol. 2019 Sep 26. pii: S0190-9622(19)32787-2. doi: 10.1016/j.jaad.2019.09.042. [Epub ahead of print] No abstract available.

2.

Tildrakizumab efficacy and impact on quality of life up to 52 weeks in patients with moderate-to-severe psoriasis: a pooled analysis of two randomized controlled trials.

Blauvelt A, Sofen H, Papp K, Gooderham M, Tyring S, Zhao Y, Lowry S, Mendelsohn A, Parno J, Reich K.

J Eur Acad Dermatol Venereol. 2019 Aug 13. doi: 10.1111/jdv.15862. [Epub ahead of print]

PMID:
31407394
3.

Sustained and continuously improved efficacy of tildrakizumab in patients with moderate-to-severe plaque psoriasis.

Elewski B, Menter A, Crowley J, Tyring S, Zhao Y, Lowry S, Rozzo S, Mendelsohn AM, Parno J, Gordon K.

J Dermatolog Treat. 2019 Jul 22:1-6. doi: 10.1080/09546634.2019.1640348. [Epub ahead of print]

PMID:
31268369
4.

Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma.

Hassan R, Kindler HL, Jahan T, Bazhenova L, Reck M, Thomas A, Pastan I, Parno J, O'Shannessy DJ, Fatato P, Maltzman JD, Wallin BA.

Clin Cancer Res. 2014 Dec 1;20(23):5927-36. doi: 10.1158/1078-0432.CCR-14-0804. Epub 2014 Sep 17.

5.

Comparison of the maximum tolerated dose (MTD) dermal response in three strains of mice following repeated exposure to acrylic acid.

McLaughlin JE, Parno J, Garner FM, Clary JJ, Thomas WC, Murphy SR.

Food Chem Toxicol. 1995 Jun;33(6):507-13.

PMID:
7797178
6.

Proquazone for tension headache--a multicenter trial.

DiSerio FJ, Friedman AP, Parno J, Singer JM.

Headache. 1985 May;25(3):127-33. No abstract available.

PMID:
3891682
7.
8.

Two-year outcome of adult intensive care patients.

Parno JR, Teres D, Lemeshow S, Brown RB, Avrunin JS.

Med Care. 1984 Feb;22(2):167-76.

PMID:
6700277
9.

Hospital charges and long-term survival of ICU versus non-ICU patients.

Parno JR, Teres D, Lemeshow S, Brown RB.

Crit Care Med. 1982 Sep;10(9):569-74.

PMID:
7105765

Supplemental Content

Support Center